Fitbit users in Belgium, the Netherlands,
Ireland and the United Kingdom can use FibriCheck to help detect
heart rhythm irregularities like Atrial Fibrillation
Fitbit (NYSE:FIT) and FibriCheck, an innovative health screening
and monitoring app, today announced a partnership enabling users in
Belgium, the Netherlands, Ireland and the UK to monitor their heart
rhythm for irregularities, such as Atrial Fibrillation (Afib)
directly from their Fitbit smartwatch. The FibriCheck software,
which is CE marked, meets the performance standards for medical
devices in the European Union (EU).
The FibriCheck app runs on Fitbit OS and uses Fitbit’s
commercial-grade PPG (photoplethysmography) sensors – light-based
technology that measures the rate of blood flow – to capture heart
rhythm measurements from a user’s wrist. The measurement assessment
can be viewed directly on the smartwatch screen and easily shared
with medical professionals via a FibriCheck web interface to help
diagnose conditions such as Afib. Afib, an irregular heart rhythm
that is often difficult to detect or diagnose because of irregular
occurrences, is a leading cause of stroke, the occurrence of which
in Europe is predicted to increase to more than 800,000 by
20351.
“For more than a decade, Fitbit has helped millions of consumers
around the world get healthier by providing them with a holistic
picture of their health and wellness. Our partnership with
FibriCheck expands on this vision by offering an accessible way for
people to detect irregular heart rhythms using their Fitbit
smartwatch, helping them to potentially identify and monitor heart
conditions like atrial fibrillation,” said Nicola Maxwell, Director
of Health Solutions & Services, EMEA for Fitbit. “FibriCheck is
the first CE-marked app to be available on Fitbit smartwatches in
the EU and its addition to the platform complements our expanding
range of technology-based solutions that can help drive positive
health outcomes.”
The FibriCheck smartphone app has been available for users to
measure their heart rhythm via the camera on their smartphones
since 2016. A clinical trial was conducted to validate and support
CE Marking of the FibriCheck application on Fitbit smartwatches.
The trial compared FibriCheck on Fitbit smartwatches to
gold-standard 12-lead ECG and state-of-the-art wearable single lead
ECG technologies. The results indicated that the FibriCheck
algorithm on Fitbit smartwatches was highly accurate in correctly
detecting the presence of Afib when compared to ECG. As a result,
this industry-leading partnership between Fitbit and FibriCheck
will make trusted heart health monitoring accessible to more
consumers in Europe.
“FibriCheck is an easy-to-use, first step for people who have
concerns about their heart health or who have been advised to
monitor their heart rhythm consistently by a medical professional,”
said Lars Grieten, CEO, FibriCheck. “By partnering with Fitbit, we
are bringing our technology to millions of consumers’ wrists
regardless of mobile device platform, and it provides an accessible
option for consumers to better understand their heart health and
then easily share those insights with a medical professional who
can support their care.”
FibriCheck will be available on Fitbit Versa™, Fitbit Versa Lite
Edition™, Fitbit Versa 2™ and Fitbit Ionic™ devices and can be
accessed through the Fitbit app gallery on smartphones. FibriCheck
has a subscription model starting at €3.99 per month and a one-day
free trial is available. A FibriCheck reading can be completed in
60 seconds. Instant, color-coded feedback is sent directly to the
smartwatch screen; from green indicating that no irregularities
have been detected, to red, which advises users to seek medical
advice. A detailed report is also available via the FibriCheck
smartphone app, which can be shared with medical professionals.
About Fitbit, Inc. (NYSE: FIT)
Fitbit helps people lead healthier, more active lives by
empowering them with data, inspiration and guidance to reach their
goals. Fitbit designs products and experiences that track and
provide motivation for everyday health and fitness. Fitbit’s
diverse line of innovative and popular products include Fitbit
Charge 3™, Fitbit Inspire HR™, Fitbit Inspire™ and Fitbit Ace 2™
activity trackers, as well as the Fitbit Ionic™ and Fitbit Versa™
family of smartwatches, Fitbit Flyer™ wireless headphones, and
Fitbit Aria family of smart scales. Fitbit products are carried in
approximately 39,000 retail stores and in 100+ countries around the
globe. Powered by one of the world’s largest databases of activity,
exercise and sleep data and Fitbit’s leading health and fitness
social network, the Fitbit platform delivers personalized
experiences, insights and guidance through leading software and
interactive tools, including the Fitbit and Fitbit Coach apps, and
Fitbit OS for smartwatches. Fitbit’s paid subscription service,
Fitbit Premium, uses your unique data to deliver actionable
guidance and coaching in the Fitbit app to help you reach your
health and fitness goals. Fitbit Health Solutions develops health
and wellness solutions designed to help increase engagement,
improve health outcomes, and drive a positive return for employers,
health plans and health systems.
Fitbit and the Fitbit logo are trademarks or registered
trademarks of Fitbit, Inc. in the U.S. and other countries.
Additional Fitbit trademarks can be found
www.fitbit.com/legal/trademark-list. Third-party trademarks are the
property of their respective owners.
Connect with us on Facebook, Instagram or Twitter and share your
Fitbit experience.
About FibriCheck
FibriCheck’s mission is to make healthcare widely available,
affordable and unlinked to time and location. FibriCheck targets
the prevention of possibly life-threatening and disabling strokes
by enabling early detection of heart rhythm disorders, with a main
focus on atrial fibrillation (Afib).
FibriCheck makes the detection of heart rhythm disorders
possible with just a smartphone or smartwatch using the clinically
validated PPG technology. The CE-marked application turns heart
rhythm monitoring into an at-home solution that can be used by
anyone at anytime, without the need for extra hardware. FibriCheck
is currently helping over 130,000 people in 43 countries and is
prescribed by more than 1,500 doctors, enabling the detection of
more than 14,000 heart rhythm disorders so far.
FibriCheck is a registered trademark of Qompium nv. in the EU
and US.
Connect with FibriCheck via the FibriCheck website or on
Facebook or Twitter.
Forward Looking Statement
This press release contains forward-looking statements, within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, that involve risks and uncertainties
including, among other things, statements regarding the future
availability of any product features or services described in this
release, future potential of the FibriCheck app described in this
release; and our ability to help users manage or improve their
health and wellness. These forward-looking statements are only
predictions and may differ materially from actual results due to a
variety of factors, including the effects of the highly competitive
market in which we operate, including competition from much larger
technology companies; any inability to successfully develop and
introduce new products, features, and services or enhance existing
products and services; product liability issues, security breaches
or other defects; and other factors discussed under the heading
“Risk Factors” in our most recent report on Form 10-Q filed with
the Securities and Exchange Commission. All forward-looking
statements contained herein are based on information available to
us as of the date hereof and we do not assume any obligation to
update these statements as a result of new information or future
events.
1"The Burden of Stroke in Europe Report | King's College London
for the ...." https://strokeeurope.eu/. Accessed 3 Sep. 2019.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190924006057/en/
Fitbit, Inc. Jen Ralls, 415-941-0037 PR@fitbit.com
Fitbit (NYSE:FIT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fitbit (NYSE:FIT)
Historical Stock Chart
From Apr 2023 to Apr 2024